| Overall | Incident type 2 diabetes | |
---|---|---|---|
Cases | Non-cases | ||
Number of individuals | 12,006 | 862 | 11,144 |
Cohort (N (%)) | Â | Â | Â |
 FINRISK | 7336 (61.1) | 531 (61.6) | 6805 (61.1) |
 PRIME Belfast | 2496 (20.8) | 240 (27.8) | 2256 (20.2) |
 KORA F4 | 2174 (18.1) | 91 (10.6) | 2083 (18.7) |
CT-proET-1, in pmol/l [mean (SD)] | 50.7 (13.4) | 55.5 (14.2) | 50.3 (13.3) |
MR-proADM, in nmol/l [geometric mean (antilog SD)] | 0.46 (1.31) | 0.52 (1.30) | 0.45 (1.30) |
Age, in years [mean (SD)] | 49.4 (11.8) | 54.7 (9.2) | 49.0 (11.8) |
Male [N (%)] | 7072 (58.9) | 615 (71.3) | 6457 (57.9) |
Body mass index, in kg/m2 [mean (SD)] | 26.5 (4.25) | 30.6 (5.04) | 26.1 (4.01) |
Waist circumference, in cm [mean (SD)] | 88.9 (12.8) | 101 (12.9) | 87.9 (12.3) |
Actual hypertension [N (%)]a | 4899 (40.8) | 608 (70.5) | 4,291 (38.5) |
Systolic blood pressure, in mmHg [mean (SD)] | 132.1 (20.1) | 144.0 (20.7) | 131.2 (19.8) |
Diastolic blood pressure, in mmHg [mean (SD)] | 81.0 (11.3) | 87.2 (11.4) | 80.5 (11.2) |
Use of antihypertensive medication [N (%)] | 1,308 (10.9) | 225 (26.1) | 1,083 (9.7) |
Current smoker [N (%)] | 3,234 (26.9) | 234 (27.1) | 3,000 (26.9) |
Total cholesterol, in mmol/l [mean (SD)] | 5.59 (1.05) | 5.89 (1.06) | 5.56 (1.05) |
HDL, in mmol/l [mean (SD)] | 1.37 (0.37) | 1.19 (0.33) | 1.39 (0.37) |
eGFR (ml/min/1.73m2) [mean (SD)] | 89.1 (19.4) | 84.8 (21.3) | 89.4 (19.2) |
Insulin (microU/ml) [geometric mean (antilog SD)] | 5.79 (1.85) | 9.04 (1.89) | 5.60 (1.82) |
hsCRP (mg/l) [geometric mean (antilog SD)] | 1.23 (3.03) | 2.19 (2.83) | 1.18 (3.01) |
Leptin (ng/ml) [geometric mean (antilog SD)] | 7.30 (2.69) | 11.07 (2.52) | 7.07 (2.69) |
Fasting glucose (mmol/l) [geometric mean (antilog SD)]b | 5.01 (1.13) | 5.45 (1.23) | 4.98 (1.12) |